{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:36:46Z","timestamp":1771648606737,"version":"3.50.1"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"1081","license":[{"start":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T00:00:00Z","timestamp":1444348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The last 90\u2005years have seen considerable advances in the management of type 1 and type 2 diabetes. Prof MacLean of Guy\u2019s Hospital wrote in the Postgraduate Medical Journal in 1926 about the numerous challenges that faced patients and their healthcare professionals in delivering safe and effective diabetes care at that time. The discovery of insulin in 1922 heralded a new age in enabling long-term glycaemic control, which reduced morbidity and mortality. Thirty years later, the first oral agents for diabetes, the biguanides and sulfonylureas, appeared and freed type 2 patients from having to inject insulin following diagnosis. Improvements in insulin formulations over the decades, including rapid-acting and long-acting insulin analogues that more closely mimic physiological insulin secretion, have increased the flexibility and efficacy of type 1 diabetes management. The last two decades have seen major advances in technology, which has manifested in more accurate glucose monitoring systems and insulin delivery devices (\u2018insulin pump\u2019). Increased understanding of the pathophysiological deficits underlying type 2 diabetes has led to the development of targeted therapeutic approaches such as on the small intestine (glucagon-like peptide-1 receptor analogues and dipeptidyl-peptidase IV inhibitors) and kidneys (sodium-glucose cotransporter-2 inhibitors). A patient-centred approach delivered by a multidisciplinary team is now advocated. Glycaemic targets are set according to individual circumstances, taking into account factors such as weight, hypoglycaemia risk and patient preference. Stepwise treatment guidelines devised by international diabetes organisations standardise and rationalise management. Structured education programmes and psychological support are now well-established as essential for improving patient motivation and self-empowerment. Large multicentre randomised trials have confirmed the effectiveness of intensive glycaemic control on microvascular outcomes, but macrovascular outcomes and cardiovascular safety remain controversial with several glucose-lowering agents. Future directions in diabetes care include strategies such as the \u2018bionic pancreas\u2019, stem cell therapy and targeting the intestinal microbiome. All of these treatments are still being refined, and it may be several decades before they are clinically useful. Prevention and cure of diabetes is the Holy Grail but remain elusive due to lack of detailed understanding of the metabolic, genetic and immunological causes that underpin diabetes. Much progress has been made since the time of Prof MacLean 90\u2005years ago, but there are still great strides to be taken before the life of the patient with diabetes improves even more significantly.<\/jats:p>","DOI":"10.1136\/postgradmedj-2014-133200","type":"journal-article","created":{"date-parts":[[2015,10,10]],"date-time":"2015-10-10T02:33:53Z","timestamp":1444444433000},"page":"612-621","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Current management of diabetes mellitus and future directions in care"],"prefix":"10.1093","volume":"91","author":[{"given":"Sudesna","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Leicester Diabetes Research Centre, University of Leicester, Leicester General Hospital , Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie J","family":"Davies","sequence":"additional","affiliation":[{"name":"Leicester Diabetes Research Centre, University of Leicester, Leicester General Hospital , Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,10,9]]},"reference":[{"key":"2023041905424454200_R1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/pgmj.1.6.73","article-title":"Some observations on diabetes and insulin in general practice","volume":"1","author":"Maclean","year":"1926","journal-title":"Postgrad Med J"},{"key":"2023041905424454200_R2","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db10-1114","article-title":"Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man","volume":"60","author":"Skyler","year":"2011","journal-title":"Diabetes"},{"key":"2023041905424454200_R5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/db13-1146","article-title":"Human \u03b2-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map","volume":"63","author":"Bernal-Mizrachi","year":"2014","journal-title":"Diabetes"},{"key":"2023041905424454200_R6","first-page":"141","article-title":"Pancreatic extracts in the treatment of diabetes mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can Med Assoc J"},{"key":"2023041905424454200_R7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1464-5491.2003.00937.x","article-title":"Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with type 2 diabetes in secondary failure: outcomes after 1 year","volume":"20","author":"Dhindsa","year":"2003","journal-title":"Diabet Med"},{"key":"2023041905424454200_R8","first-page":"682","article-title":"Bariatric surgery versus intensive medical therapy for diabetes","volume":"371","author":"Schauer","year":"2014","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(57)91023-1","article-title":"Clinical studies on the hypoglycaemic action of the sulphonylureas","volume":"269","author":"Butterfield","year":"1957","journal-title":"Lancet"},{"key":"2023041905424454200_R10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/diab.7.6.468","article-title":"Clinical use of the biguanides and their role in stabilizing juvenile-type diabetes","volume":"7","author":"Krall","year":"1958","journal-title":"Diabetes"},{"key":"2023041905424454200_R11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543784.2014.909407","article-title":"Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes","volume":"23","author":"Lamos","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"2023041905424454200_R12","first-page":"923","article-title":"Incretin-based therapy in patients with type 1 diabetes mellitus","volume":"69","author":"Miyagawa","year":"2011","journal-title":"Nihon Rinsho"},{"key":"2023041905424454200_R13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bmj.325.7367.746","article-title":"Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial","volume":"325","author":"DAFNE Study Group","year":"2002","journal-title":"BMJ"},{"key":"2023041905424454200_R14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/dc12-0080","article-title":"Structured type 1 diabetes education delivered within routine care: impact on glycemic control and diabetes-specific quality of life","volume":"36","author":"Cooke","year":"2013","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/dme.12270","article-title":"The cost-effectiveness of the dose adjustment for normal eating (DAFNE) structured education programme: An update using the sheffield type 1 diabetes policy model","volume":"30","author":"Kruger","year":"2013","journal-title":"Diabet Med"},{"key":"2023041905424454200_R16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/bmj.39474.922025.BE","article-title":"Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial","volume":"336","author":"Davies","year":"2008","journal-title":"BMJ"},{"key":"2023041905424454200_R17","doi-asserted-by":"crossref","first-page":"e2333","DOI":"10.1136\/bmj.e2333","article-title":"Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care","volume":"344","author":"Khunti","year":"2012","journal-title":"BMJ"},{"key":"2023041905424454200_R18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"2023041905424454200_R19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"2023041905424454200_R20","first-page":"336","article-title":"Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes","volume":"17","author":"Mannucci","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"2023041905424454200_R21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"key":"2023041905424454200_R22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-014-3417-3","article-title":"The safety of sulfonylurea therapy in type 2 diabetes: have we reached the practical limits of our evidence base?","volume":"58","author":"Johnson","year":"2015","journal-title":"Diabetologia"},{"key":"2023041905424454200_R23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"2023041905424454200_R24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/dom.12101","article-title":"Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?","volume":"15","author":"Consoli","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2023041905424454200_R25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1572-0241.2000.01707.x","article-title":"Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the united states food and drug administration","volume":"95","author":"Kohlroser","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2023041905424454200_R26","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R27","doi-asserted-by":"crossref","first-page":"e4541","DOI":"10.1136\/bmj.e4541","article-title":"Meta-analysis confirms raised risk of bladder cancer from pioglitazone","volume":"345","author":"Kermode-Scott","year":"2012","journal-title":"BMJ"},{"key":"2023041905424454200_R28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2023041905424454200_R29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"2023041905424454200_R30","first-page":"CG87","volume-title":"Type 2 diabetes: the management of type 2 diabetes","author":"NICE","year":"2009"},{"key":"2023041905424454200_R31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023041905424454200_R32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023041905424454200_R33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2023041905424454200_R34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"2023041905424454200_R35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/dme.12497","article-title":"Polypharmacy in people with type 1 and type 2 diabetes is justified by current guidelines\u2013a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems","volume":"31","author":"Bauer","year":"2014","journal-title":"Diabet Med"},{"key":"2023041905424454200_R37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","article-title":"Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials","volume":"5","author":"Vora","year":"2014","journal-title":"Diabetes Ther"},{"key":"2023041905424454200_R38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/dc10-1915","article-title":"Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes","volume":"34","author":"Johnston","year":"2011","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2023041905424454200_R41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/dmrr.2557","article-title":"Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomised controlled cross-over trial","volume":"31","author":"Tumminia","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"2023041905424454200_R42","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jama.2013.277818","article-title":"Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial","volume":"310","author":"Ly","year":"2013","journal-title":"JAMA"},{"key":"2023041905424454200_R43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijpharm.2014.10.039","article-title":"Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading","volume":"477","author":"Li","year":"2014","journal-title":"Int J Pharm"},{"key":"2023041905424454200_R44","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1517\/17425247.2015.990436","article-title":"Newer devices and improved formulations of inhaled insulin","volume":"12","author":"Rashid","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"2023041905424454200_R45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2337\/dc11-1243","article-title":"Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young","volume":"35","author":"Thanabalasingham","year":"2012","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R46","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"issue":"(Suppl 2)","key":"2023041905424454200_R47","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.2337\/dc11-s225","article-title":"Insulin: potential negative consequences of early routine use in patients with type 2 diabetes","volume":"34","author":"Lebovitz","year":"2011","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R48","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4158\/EP13337.OR","article-title":"How well do self-monitored capillary glucose measurements predict the mean blood glucose from 24-hour continuous monitoring in endocrine practice?","volume":"20","author":"Gioe","year":"2014","journal-title":"Endocr Pract"},{"key":"2023041905424454200_R49","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1515\/cclm-2013-5001","article-title":"Standardization and analytical goals for glycated hemoglobin measurement","volume":"51","author":"Braga","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"2023041905424454200_R50","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2337\/dc14-0984","article-title":"Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment","volume":"37","author":"Pasquel","year":"2014","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R51","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2337\/dc12-2508","article-title":"Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action","volume":"36","author":"Draznin","year":"2013","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R52","article-title":"Diabetes patients develop preventable complications in hospital and access to specialist staff is inadequate","author":"Health and Social Care Information Centre (HSCIC)"},{"key":"2023041905424454200_R53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7861\/clinmedicine.12-2-137","article-title":"Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality","volume":"12","author":"Evans","year":"2012","journal-title":"Clin Med"},{"key":"2023041905424454200_R54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcjd.2014.01.002","article-title":"Safe and appropriate use of insulin and other antihyperglycemic agents in hospital","volume":"38","author":"Cornish","year":"2014","journal-title":"Can J Diabetes"},{"key":"2023041905424454200_R55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R56","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","article-title":"Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease","volume":"167","author":"Franco","year":"2007","journal-title":"Arch Intern Med"},{"key":"2023041905424454200_R57","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R58","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2023041905424454200_R61","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2023041905424454200_R62","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"2023041905424454200_R63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1745-6215-8-21","article-title":"Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins","volume":"8","author":"De Berardis","year":"2007","journal-title":"Trials"},{"key":"2023041905424454200_R64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1874364101307010004","article-title":"Diabetic retinopathy and VEGF","volume":"7","author":"Gupta","year":"2013","journal-title":"Open Ophthalmol J"},{"issue":"(Suppl)","key":"2023041905424454200_R65","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2337\/dc15-S012","article-title":"(9) Microvascular complications and foot care","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R66","article-title":"Foot care for people with diabetes in the NHS in England: The economic case for change","author":"NHS"},{"key":"2023041905424454200_R67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"2023041905424454200_R68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1006\/jaut.1994.1040","article-title":"Prevention of diabetes and insulitis by neonatal intrathymic islet administration in NOD mice","volume":"7","author":"Charlton","year":"1994","journal-title":"J Autoimmun"},{"key":"2023041905424454200_R70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"2023041905424454200_R71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.297.14.1568","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus","volume":"297","author":"Voltarelli","year":"2007","journal-title":"JAMA"},{"key":"2023041905424454200_R72","first-page":"211","article-title":"Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges","volume":"7","author":"Bruni","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2023041905424454200_R73","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2337\/dc12-0063","article-title":"Improvement in outcomes of clinical islet transplantation: 1999\u20132010","volume":"35","author":"Barton","year":"2012","journal-title":"Diabetes Care"},{"key":"2023041905424454200_R74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1056\/NEJMoa1314474","article-title":"Outpatient glycemic control with a bionic pancreas in type 1 diabetes","volume":"371","author":"Russell","year":"2014","journal-title":"N Engl J Med"},{"key":"2023041905424454200_R75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2337\/dc14-0769","article-title":"Insights into the role of the microbiome in obesity and type 2 diabetes","volume":"38","author":"Hartstra","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/91\/1081\/612\/49960518\/postgradmedj-91-612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/91\/1081\/612\/49960518\/postgradmedj-91-612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T05:46:25Z","timestamp":1681883185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/91\/1081\/612\/6994961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,9]]},"references-count":75,"journal-issue":{"issue":"1081","published-online":{"date-parts":[[2015,10,9]]},"published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2014-133200","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11]]},"published":{"date-parts":[[2015,10,9]]}}}